Clinical Trial Update: Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating upfront treatment with elotuzumab, carfilzomib, lenalidomide, and dexamethasone in multiple myeloma has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Decadron (Dexamethasone)
• Empliciti (elotuzumab)
• Kyprolis (carfilzomib)
• Revlimid (lenalidomide)

Snippet

Sponsor: University of Chicago | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2025-09-10